Objective: To investigate the expression of Circ_cgga162 in serum of mantle cell lymphoma (MCL) patients and analyze its potential as a prognostic biomarker.
Methods: The expression of Circ_cgga162 in 86 cases of mantle cell lymphoma and 50 cases of lymph node reactive hyperplasia (RH) were detected by real-time quantitative polymerase chain reaction (qRT-PCR). The relationship between the expression of Circ_cgga162 and clinicopathological features was analyzed by univariate analysis. The relationship of Circ_cgga162 expression with progression-free survival time and overall survival time was analyzed by Kaplan-Meier. The relationship between expression of Circ_cgga162 and prognosis of patients was analyzed by univariate and multivariate analysis.
Results: The expression level of Circ_cgga162 in MCL patients was significantly higher than that in control (RH) group (P＜0.01). The expression of Circ_cgga162 not correlated with age, gender, B symptoms and LDH (all P＞0.05), but correlated with the expression of MCL International Prognostic Index (IPI), Ann Arbor stage, bone marrow infiltration and Ki67 (all P＜0.05). In addition, Kaplan-Meier analysis showed that the progression-free survival time and overall survival time of the MCL patients with high expression of Circ_cgga162 were significantly shorter than those of the MCL patients with low expression (P＜0.01). Univariate analysis showed that Ann Arbor stage, Circ_cgga162 expression, MIPI, bone marrow infiltration and Ki67 were the prognostic factors for MCL patients (all P＜0.05). Multivariate Cox regression analysis showed that Ann Arbor stage, Circ_cgga162 expression and MIPI were independent factors affecting the prognosis of MCL patients (all P＜0.05).
Conclusion: Circ_cgga162 is highly expressed in serum of patients MCL, which relates with the prognosis of MCL patients. Circ_cgga162 can be used as a potential prognostic marker and therapeutic target for MCL patients.
题目: Circ_cgga162在套细胞淋巴瘤患者中的表达及意义.
目的: 探讨Circ_cgga162在套细胞淋巴瘤（mantle cell lymphoma，MCL）患者血清中的表达，并分析其作为预后生物标志物的潜力.
方法: 采用实时定量聚合酶链反应（QRT-PCR）检测86例套细胞淋巴瘤患者和50例淋巴结反应性增生（RH）患者血清中Circ_cgga162的表达，分析Circ_cgga162表达与临床病理特征的关系。使用SPSS软件，采用单因素-生存分析法（Kaplan-Meier）分析Circ_cgga162的表达与患者无进展生存时间及总生存时间之间的关系；单因素及多因素分析Circ_cgga162表达与患者临床预后的关系.
结果: MCL患者血清中Circ_cgga162的表达水平明显高于RH组（P＜0.01）。单因素分析提示，Circ_cgga162的表达与患者的年龄、性别、B症状、LDH均无明显关系（P＞0.05）；而与淋巴瘤国际预后指数（MCL International Prognostic Index，IPI）、Ann Arbor分期、骨髓浸润及Ki67的表达均明显相关（P＜0.05）。Kaplan-Meier分析显示，Circ_cgga162高表达患者的无进展生存时间及总生存期明显短于低表达的患者（P＜0.001）。单因素分析提示，Ann Arbor分期、Circ_cgga162表达、MIPI、骨髓浸润及Ki67均是影响MCL患者预后的因素（P＜0.05）；多因素Cox回归分析发现，Ann Arbor分期、Circ_cgga162表达及MIPI均是影响MCL患者预后的独立因素（P＜0.05）.
结论: Circ_cgga162在MCL患者组织中高表达，与患者的预后相关，可作为MCL患者潜在的预后标志物和治疗靶点.